Bibliography
- Harousseau JL, Attal M, Avet-Loiseau H, Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 Phase III trial. J Clin Oncol 2010;28(30):4621-9
- Harousseau JL, Attal M, Avet-Loiseau H. The role of complete response in multiple myeloma. Blood 2009;114(15):3139-46
- van de Velde HJ, Liu X, Chen G, Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica 2007;92(10):1399-406
- Haessler J, Shaughnessy JD Jr, Zhan F, Benefit of complete response in multiple myeloma limited to high-risk subgroup identified by gene expression profiling. Clin Cancer Res 2007;13(23):7073-9
- McCarthy PL, Owzar K, Anderson KC, Phase III intergroup study of lenalidomide versus placebo maintenance therapy following single autologous stem cell transplant (ASCT) for multiple myeloma (MM): CALGB 100104. ASCO Meeting Abstracts. 2010;28(15 Suppl):8017
- Attal M, Lauwers Vc, Marit G, Maintenance treatment with lenalidomide after transplantation for MYELOMA: Final analysis of the IFM 2005-02. ASH Annual Meeting Abstracts. Blood 2010;116(21):310
- Harousseau J-L, Avet-Loiseau H, Facon T, Bortezomib Plus Dexamethasone (VD)Versus Reduced-dose bortezomib Plus Thalidomide Plus Dexametasone (vTD) as Induction Treatment Prior to Autologous Stem-Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (MM). ASH Annual Meeting Abstracts 2009;114(22):354
- Sonneveld P, Schmidt-Wolf I, van der Holt B, HOVON-65/GMMG-HD4 Randomized Phase III Trial Comparing Bortezomib, Doxorubicin, Dexamethasone (PAD) Vs VAD Followed by High-Dose Melphalan (HDM) and Maintenance with Bortezomib or Thalidomide In Patients with Newly Diagnosed Multiple Myeloma (MM). ASH Annual Meeting Abstracts 2010;116(21):40
- Einsele H, Liebisch P, Langer C, Velcade, Intravenous Cyclophosphamide and Dexamethasone (VCD) Induction for Previously Untreated Multiple Myeloma (German DSMM XIa Trial). ASH Annual Meeting Abstracts 2009;114(22):131
- Reeder CB, Reece DE, Kukreti V, Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a Phase II clinical trial. Leukemia 2009;23(7):1337-41
- Richardson PG, Weller E, Lonial S, Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 2010;116(5):679-86
- Kumar SK, Flinn I, Noga SJ, Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: Phase 1 results from the multicenter evolution study. Leukemia 2010;24(7):1350-6